"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 5 | 1 | 6 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 4 | 0 | 4 |
| 2019 | 4 | 0 | 4 |
| 2020 | 4 | 2 | 6 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Anti-SARS-CoV-2 Small Molecule Targeting of Oxysterol-Binding Protein (OSBP) Activates Cellular Antiviral Innate Immunity. ACS Infect Dis. 2025 May 09; 11(5):1064-1077.
-
Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review. Viruses. 2025 Jan 18; 17(1).
-
Postnatal cytomegalovirus infection and pulmonary vascular disease in extremely premature infants: A case series. J Neonatal Perinatal Med. 2024; 17(2):275-284.
-
Design and Development of Robust, Daylight-Activated, and Rechargeable Biocidal Polymeric Films as Promising Active Food Packaging Materials. ACS Appl Bio Mater. 2023 06 19; 6(6):2459-2467.
-
Structure-Activity Relationships of Ligand Binding to Oxysterol-Binding Protein (OSBP) and OSBP-Related Protein 4. J Med Chem. 2023 03 23; 66(6):3866-3875.
-
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Infect. 2023 03; 86(3):248-255.
-
A Case of Orbital Apex Syndrome as a Complication of Herpes Zoster Ophthalmicus. R I Med J (2013). 2022 Dec 01; 105(10):49-51.
-
What barriers delay treatment in patients with hepatitis C? J Fam Pract. 2022 09; 71(7):E22-E24.
-
Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. Am J Pathol. 2022 09; 192(9):1282-1294.
-
A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH. Curr Eye Res. 2022 07; 47(7):1087-1093.